Similarly, the inhibitor of cyclin-dependent kinase 9 (CDK9) induced AML apoptosis by down-regulating the expression of MCL1 and demonstrated anti-leukemia and clinical activity in refractory and relapsed (R/R) AML (47, 108) (Table 1). This evidence concerns the gene MCL1 and acute myeloid leukemia.